Astellas Pharma Inc.

Symbol: ALPMF

PNK

10.035

USD

Market price today

  • 216.8874

    P/E Ratio

  • -0.0728

    PEG Ratio

  • 17.99B

    MRK Cap

  • 0.00%

    DIV Yield

Astellas Pharma Inc. (ALPMF) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.80%

Operating Profit Margin

0.07%

Net Profit Margin

0.01%

Return on Assets

0.00%

Return on Equity

0.01%

Return on Capital Employed

0.05%

Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO:Mr. Naoki Okamura BSc
Full-time employees:14484
City:Tokyo
Address:2-5-1, Nihonbashi-Honcho
IPO:2010-04-26
CIK:

Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platform, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. The company has a strategic collaboration and license agreement with Minovia Therapeutics Ltd. for the research, development, and commercialization of cell therapy programs for diseases caused by mitochondrial dysfunction. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.

General Outlook

When we look at how much money they make before expenses, they keep 0.797% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.067%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.008%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.004% return, is a testament to Astellas Pharma Inc.'s adeptness in optimizing resource deployment. Astellas Pharma Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.008%. Furthermore, the proficiency of Astellas Pharma Inc. in capital utilization is underscored by a remarkable 0.047% return on capital employed.

Stock Prices

Astellas Pharma Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $11.09, while its low point bottomed out at $11.09. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Astellas Pharma Inc.'s stock market.

Liquidity Ratios

Analyzing ALPMF liquidity ratios reveals its financial health of the firm. The current ratio of 92.92% gauges short-term asset coverage for liabilities. The quick ratio (68.73%) assesses immediate liquidity, while the cash ratio (26.11%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio92.92%
Quick Ratio68.73%
Cash Ratio26.11%

Profitability Ratios

ALPMF profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 1.47% underscores its earnings before tax deductions. The effective tax rate stands at 33.67%, revealing its tax efficiency. The net income per EBT, 54.84%, and the EBT per EBIT, 21.85%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 6.72%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin1.47%
Effective Tax Rate33.67%
Net Income per EBT54.84%
EBT per EBIT21.85%
EBIT per Revenue6.72%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 0.93, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding69
Days of Inventory Outstanding279
Operating Cycle403.97
Days of Payables Outstanding208
Cash Conversion Cycle196
Receivables Turnover2.93
Payables Turnover1.76
Inventory Turnover1.31
Fixed Asset Turnover5.46
Asset Turnover0.45

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 97.64, and free cash flow per share, 51.62, depict cash generation on a per-share basis. The cash per share value, 187.23, showcases liquidity position. A payout ratio of 9.04 highlights the portion of earnings distributed as dividends. Lastly, the operating cash flow sales ratio, 0.11, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share97.64
Free Cash Flow per Share51.62
Cash per Share187.23
Payout Ratio9.04
Operating Cash Flow Sales Ratio0.11
Free Cash Flow to Operating Cash Flow Ratio0.53
Cash Flow Coverage Ratio0.19
Short Term Coverage Ratio0.37
Capital Expenditure Coverage Ratio2.12
Dividend Paid and Capex Coverage Ratio0.88
Dividend Payout Ratio0.04

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 25.77%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.58, we discern the balance between debt and equity financing. The long-term debt to capitalization, 21.91%, and total debt to capitalization, 36.57%, ratios shed light on its capital structure. An interest coverage of 8.97 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio25.77%
Debt Equity Ratio0.58
Long Term Debt to Capitalization21.91%
Total Debt to Capitalization36.57%
Interest Coverage8.97
Cash Flow to Debt Ratio0.19
Company Equity Multiplier2.24

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 894.27, provides a glimpse into top-line earnings distributed across each share. Net income per share, 9.50, reflects the portion of profit attributed to each share. The book value per share, 889.98, represents the net asset value distributed per share, while the tangible book value per share, -154.20, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share894.27
Net Income Per Share9.50
Book Value Per Share889.98
Tangible Book Value Per Share-154.20
Shareholders Equity Per Share889.98
Interest Debt Per Share519.73
Capex Per Share-46.00

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 5.60%, indicates top-line expansion, while the gross profit growth, -1.45%, reveals profitability trends. EBIT growth, 33.86%, and operating income growth, 33.86%, offer insights into operational profitability progression. The net income growth, -82.73%, showcases bottom-line expansion, and the EPS growth, -82.49%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth5.60%
Gross Profit Growth-1.45%
EBIT Growth33.86%
Operating Income Growth33.86%
Net Income Growth-82.73%
EPS Growth-82.49%
EPS Diluted Growth-82.49%
Weighted Average Shares Growth-1.47%
Weighted Average Shares Diluted Growth-1.39%
Dividends per Share Growth17.97%
Operating Cash Flow Growth-44.68%
Free Cash Flow Growth-58.69%
10-Year Revenue Growth per Share76.24%
5-Year Revenue Growth per Share32.25%
3-Year Revenue Growth per Share32.91%
10-Year Operating CF Growth per Share6.02%
5-Year Operating CF Growth per Share-24.47%
3-Year Operating CF Growth per Share-38.80%
10-Year Net Income Growth per Share-76.50%
5-Year Net Income Growth per Share-91.74%
3-Year Net Income Growth per Share-85.36%
10-Year Shareholders Equity Growth per Share57.62%
5-Year Shareholders Equity Growth per Share36.63%
3-Year Shareholders Equity Growth per Share19.24%
10-Year Dividend per Share Growth per Share149.14%
3-Year Dividend per Share Growth per Share58.63%
Receivables Growth22.74%
Inventory Growth42.64%
Asset Growth45.31%
Book Value per Share Growth7.42%
Debt Growth359.99%
R&D Expense Growth6.54%
SGA Expenses Growth17.43%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 3,621,853,664,174.64, captures the company's total value, considering both debt and equity. Income quality, 10.64, assesses the reliability of reported earnings. The ratio of intangibles to total assets, 52.46%, indicates the value of non-physical assets, and capex to operating cash flow, -45.50%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value3,621,853,664,174.64
Income Quality10.64
Research and Development to Revenue18.34%
Intangibles to Total Assets52.46%
Capex to Operating Cash Flow-45.50%
Capex to Revenue-5.14%
Capex to Depreciation-52.27%
Graham Number436.27
Return on Tangible Assets1.00%
Graham Net Net-614.81
Working Capital-90,995,000,000
Tangible Asset Value-276,530,000,000
Net Current Asset Value-778,885,000,000
Invested Capital1
Average Receivables497,276,000,000
Average Payables162,714,500,000
Average Inventory211,562,000,000
Days Sales Outstanding125
Days Payables Outstanding173
Days of Inventory On Hand232
ROIC5.08%
ROE0.01%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 1.75, and the price to book ratio, 1.75, reflect the market's valuation relative to the company's book value. The price to sales ratio, 1.75, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 30.25, and price to operating cash flows, 15.99, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio1.75
Price to Book Ratio1.75
Price to Sales Ratio1.75
Price Cash Flow Ratio15.99
Price Earnings to Growth Ratio-0.07
Enterprise Value Multiple8.42
Price Fair Value1.75
Price to Operating Cash Flow Ratio15.99
Price to Free Cash Flows Ratio30.25
Price to Tangible Book Ratio1.90
Enterprise Value to Sales2.26
Enterprise Value Over EBITDA10.78
EV to Operating Cash Flow19.97
Earnings Yield0.56%
Free Cash Flow Yield3.25%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Astellas Pharma Inc. (ALPMF) on the PNK in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 216.887 in 2024.

What is the ticker symbol of Astellas Pharma Inc. stock?

The ticker symbol of Astellas Pharma Inc. stock is ALPMF.

What is company IPO date?

IPO date of Astellas Pharma Inc. is 2010-04-26.

What is company current share price?

Current share price is 10.035 USD.

What is stock market cap today?

The market cap of stock today is 17993741671.000.

What is PEG ratio in 2024?

The current -0.073 is -0.073 in 2024.

What is the number of employees in 2024?

In 2024 the company has 14484.